XOMA News and Press, XOMA Corporation From 07/28/21

EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.  NIS793 is a potential...

XOMA Corporation (XOMA) has acquired the royalty interest position Kuros Biosciences (CSBTF) holds in Checkmate Pharmaceuticals’ vidutolimod (CMP-001).Kuros will receive an initial upfront payment of $7M, may receive up to $24M in pre-commercial milestones from Checkmate and is eligibl...

SCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (N...

EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod (CMP-001), an advanced-generation Toll-like receptor 9 agonist packag...

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferr...

EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8, 2021, in a virtual setting. “W...

XOMA (XOMA): Q1 GAAP EPS of -$0.70 misses by $0.55.Revenue of $0.4M (-50.0% Y/Y) misses by $1.66M.Company ended the first quarter of 2021 with $67.8M in cash.The Company continues to believe its current cash position will be sufficient to fund XOMA’s operations for multiple years.Share...

XOMA’s portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash.  The April 2021 $40 million Series B Perpetual Preferred Stock offering paying 8.375% dividend increase...

XOMA (XOMA) announces that it has earned a $0.5M milestone payment from Janssen Biotech, as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of Janssen’s biologic products.Under the terms of the agreement, XOMA has the potential to receive additional ...

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinica...